- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Strategic Plan Theme: Research
Goals and progress to 2024
1.1 Develop the mechanistic understanding, technology, and translational strategies to find treatments for all human diseases
-
Support and create expert-led technology centers (instrumentation and people) to lower access barriers to methodological innovations and to accelerate groundbreaking research.
Progress to 2024:
- Small Molecule Discovery Center – Charles Hart, new director.
- NMR structure determination and drug discovery accelerated by new AI methods.
-
Build and grow collaborative teams to work on cross-cutting challenges that bridge the gap from atoms to organisms and populations.
Progress to 2024:
-
DARPA grant for anesthesia innovation (Shoichet, Sello, Manglik, Irwin, Basbaum, Hibbs).
-
Center for Collaborative Innovation (CCI): collaboration event, MAKK grants (Guo).
-
QBI collaborative opportunities: multiple RFAs throughout the year, including QCRG (infectious disease), UCD (drug/drug target discovery), CCMI (cancer).
-
-
Build teams to integrate discovery, translational pharmacology and regulatory science to develop new therapeutic agents and modalities.
-
Establish drug-focused research as a pillar of the campus precision medicine initiative
1.2 Optimize health and care delivery through clinical and health services research affecting medications, tests, devices and delivery innovations
-
Create and support collaborations that assess the clinical effectiveness, preferences, cost-effectiveness, budget impact, and health equity impact of health technologies to inform appropriate and efficient use to achieve optimal health outcomes.
Progress to 2024:
-
Preclinical design and clinical translation of TB regimens (PReDicTR) Consortium (Savic).
-
Natl Academy Med Committee: Strategies to align investments in innovations for therapeutic disease burden and unmet needs (Phillips).
-
Health equity study that determined the clinical validity of understudied candidate functional SLCO1B1 variants common in understudied groups. (Oni-Orisan and collaborators at UCSF, Stanford and Kaiser).
-
-
Create and support collaborations that assess health policies, access to health technologies, quality of care, cost, the relationship between quality and cost, and the impact on health outcomes.
1.3 Harness and conduct research that transforms PharmD education
-
Create a collaborative educational research hub that provides funding, support, and faculty and trainee development for conducting and disseminating educational research.
Progress to 2024:
Multiple presentations at AACP, AERA, AMME, CSHP; received AACP Assessment and Emerging Teaching Scholar Awards; multiple funded CFE Innovations for Education grants (Armstrong, Cat, Chun, Clinard, Floren, Gruenberg, Hsia, MacDougall, Pon, Shin, Takhar, Watanabe).
-
Apply theory, analysis, and experimentation to solve challenges in health professions education.
Progress to 2024:
Developed and launched a two-year Health Equity Curriculum in 2024 with sustainably funded near-peer student instructor internships (Hsia, Tuan).
1.4 Enable and reward entrepreneurship of our faculty, staff, and trainees, who found and collaborate with companies and engage in other strategic partnerships
-
Create an environment that supports entrepreneurship and other efforts to derive societal benefit from our research discoveries, utilizing resources with SOP and QBI, advocating for beneficial changes at the university and systemwide levels, and developing new external partnerships with a resulting financial benefit to SOP, departments, laboratories and inventors.
Progress to 2024:
Rezo: integrated mapping of disease networks for precision therapeutics (Krogan, Jura, Shokat, Bandyopadhyay).
-
Strengthen existing partnerships and programs (such as with venture capital, philanthropy) for funding and connections to resources (such as technology centers, incubators) to facilitate product development.
1.5 Harness innovations in artificial intelligence to accelerate and integrate discovery and translational research by expanding existing strengths and through new faculty recruitment
Progress to 2024:
New BTS faculty hire expands strength in genomics and AI (Calderon).
September 2024 Strategic Plan Retreat
Co-leads | Robin Corelli and Tanja Kortemme |
---|---|
Members | Steve Altschuler, Bill DeGrado, Bo Huang, Akinyemi Oni-Orisan, Kathryn Phillips, Catera Wilder |
Challenges |
|
Future directions |
|